Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Buy” by Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $260.50.

Several equities analysts recently commented on KRYS shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Bank of America upped their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday. Zacks Research upgraded shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a research report on Friday.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 13.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada increased its holdings in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares in the last quarter. United Services Automobile Association acquired a new position in shares of Krystal Biotech during the 1st quarter valued at $305,000. Finally, Empowered Funds LLC bought a new position in Krystal Biotech during the first quarter worth $218,000. Institutional investors own 86.29% of the company’s stock.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

Krystal Biotech Trading Up 5.0%

NASDAQ:KRYS opened at $261.41 on Friday. The stock has a 50 day simple moving average of $227.55 and a 200 day simple moving average of $182.63. The stock has a market cap of $7.58 billion, a P/E ratio of 39.19 and a beta of 0.46. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $267.48.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. As a group, sell-side analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.